fashion -WSS

fashion

author：explore 2025-09-27 22:18:08 - browse：2986

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Humana cuts profit projections as Medicare Advantage costs soar

WSS

Intellia plays down concerns on accidental germline transmission

Francis Collins on trust in science and how Covid communications failed

As obesity drug market grows, telehealth companies court payers

Trans patients at the end of life deserve respect and dignity

FDA advisory panel to debate high blood pressure devices

New brain studies show LSD's effects on the brain in full color

focus

fashion

leisure time

Tori Bowie and the unacceptable rates of Black maternal death

The surgeon had a dilemma only a Nazi medical text could resolve

ChatGPT in medicine: STAT answers readers' burning questions

Trans patients at the end of life deserve respect and dignity

Alkermes shareholders re

How digital therapeutics firms are pivoting after Pear's bankruptcy

Trump demands the U.S. pay no more for drugs than other countries … again

Wegovy improves function in certain heart failure patients

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

California store owner shot dead in dispute over displaying Pride flag: Police

hotspot

FDA greenlights medical device to combat bladder issues

People can get long Covid without testing positive for virus: Study

Copay coupons to count toward deductibles, after Biden court move

California store owner shot dead in dispute over displaying Pride flag: Police

Eli Lilly, Pfizer, and others want in on the online prescription market

Republicans love RFK Jr. What's that tell us about health in 2024?

knowledge

entertainment

Wikipedia

hotspot